Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu

Clin Mol Hepatol. 2024;30(2):279-280. Published online March 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0191

View: 1839 Download: 46 Web of Science: 1 Crossref: 1

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Yuchen Liu, Xiaohui Wang, Yingzi Yang

Clin Mol Hepatol. 2020;26(4):742-750. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0178

View: 7939 Download: 206 Web of Science: 36 Crossref: 36

David Tornai, Gyongyi Szabo

Clin Mol Hepatol. 2020;26(4):686-696. Published online September 28, 2020

DOI: https://doi.org/10.3350/cmh.2020.0145

View: 6277 Download: 222 Web of Science: 16 Crossref: 16

1 |

Viewed By 5505	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5409	MAFLD: How is it different from NAFLD?
Viewed By 5220	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5098	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4732	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 176	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 113	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 90	MAFLD: How is it different from NAFLD?
Cited By 80	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search